17-ethoxycarbonyl-6-methoxy-morphinan | 36397-15-6

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 吗啡烷
• 英文名称: 17-ethoxycarbonyl-6-methoxy-morphinan
• 英文别名: N-ethoxycarbonyl-3-methoxy-morphinan；17-Ethoxycarbonyl-3-methoxymorphinan；ethyl (1R,9R,10R)-4-methoxy-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-triene-17-carboxylate
• CAS: 36397-15-6
• 化学式: C₂₀H₂₇NO₃
• 分子量: 329.439
• InChiKey: PQYFVPFRIKQRBG-ILZDJORESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  24
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.65
• 拓扑面积：
  38.8
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  17-ethoxycarbonyl-6-methoxy-morphinan 在 lithium aluminium deuteride 作用下， 以 四氢呋喃 为溶剂， 反应 2.0h， 以89%的产率得到[18,18,18-2H3]-6-methoxy-17-methyl-morphinan
  参考文献：
  名称：

  Synthesis of [²H₃]-dextromethorphan and its major urinary metabolites [²H₃]-dextrorphan and [²H₃]-dextrorphan-β-glucuronide

  摘要：

  从右美沙芬开始，以[2H3]-右美沙芬和[2H3]-右美沙芬为中间体，分四步合成了[2H3]-右美沙芬-β-葡萄糖醛酸苷，总收率为 11%。Copyright © 2002 John Wiley & Sons, Ltd. All Rights Reserved.

  DOI：

  10.1002/jlcr.640
• 作为产物：
  描述：

  氯甲酸乙酯 、 左美沙芬 在 碳酸氢钠 作用下， 以 氯仿 为溶剂， 反应 5.0h， 以78.8%的产率得到17-ethoxycarbonyl-6-methoxy-morphinan
  参考文献：
  名称：

  Synthesis of [²H₃]-dextromethorphan and its major urinary metabolites [²H₃]-dextrorphan and [²H₃]-dextrorphan-β-glucuronide

  摘要：

  从右美沙芬开始，以[2H3]-右美沙芬和[2H3]-右美沙芬为中间体，分四步合成了[2H3]-右美沙芬-β-葡萄糖醛酸苷，总收率为 11%。Copyright © 2002 John Wiley & Sons, Ltd. All Rights Reserved.

  DOI：

  10.1002/jlcr.640

文献信息

• Synthesis of [2H]-labelled phase-I-metabolites using 1-[2H]-pyridinium hydrochloride
  作者：Georg Heinkele、Thomas E. Mürdter

  DOI：10.1002/jlcr.941

  日期：2005.5

  Simultaneous O-demethylation and hydrogen/deuterium exchange of aryl-methyl-ethers can be obtained using 1-[2H]-pyridinium hydrochloride as reagent at 220°C for 6 h. This reaction was applied to dextromethorphan and various non-steroidal anti-inflammatory drugs. Copyright © 2005 John Wiley & Sons, Ltd.

  使用 1-[2H]-吡啶鎓盐酸盐作为试剂在 220°C 下进行 6 小时，可以同时获得 O-去甲基化和芳基-甲基-醚的氢/氘交换。该反应适用于右美沙芬和各种非甾体抗炎药。版权所有 © 2005 John Wiley & Sons, Ltd.
• [EN] DEUTERATED MORPHINAN COMPOUNDS FOR USE IN TREATING AGITATION<br/>[FR] COMPOSÉS DE MORPHINANE DEUTÉRÉ UTILISÉS POUR LE TRAITEMENT DE L'AGITATION
  申请人：CONCERT PHARMACEUTICALS INC

  公开号：WO2017020002A1

  公开（公告）日：2017-02-02

  This invention relates to methods of treating agitation comprising administering a morphinan compound or a pharmaceutically acceptable salt thereof. This invention also provides the use in methods of treating agitation and related disorders with such a morphinan compound in combination with quinidine, or pharmaceutically acceptable salt of either or both thereof.

  本发明涉及治疗焦虑的方法，包括给予吗啡酮化合物或其药用盐。本发明还提供了在治疗焦虑和相关疾病的方法中，将这种吗啡酮化合物与奎尼丁或两者中的任何一个或两者的药用盐结合使用。
• COMBINATION OF MORPHINAN COMPOUNDS AND ANTIDEPRESSANT FOR THE TREATMENT OF PSEUDOBULBAR AFFECT, NEUROLGICAL DISEASES, INTRACTABLE AND CHRONIC PAIN AND BRAIN INJURY
  申请人：Concert Pharmaceuticals, Inc.

  公开号：US20160143902A1

  公开（公告）日：2016-05-26

  Provided herein are compositions comprising a dextromethorphan analog according to Formula I or Formula II or a pharmaceutically acceptable salt thereof of either of the foregoing, and a co-agent, e.g., an antidepressant such as a serotonin norepinephrine reuptake inhibitor; a serotonin noradrenaline dopamine reuptake inhibitor; a norepinephrine dopamine reuptake inhibitor; a monoamine oxidase inhibitor; a selective serotonin reuptake inhibitor; and a tricyclic antidepressant or a pharmaceutically acceptable salt of any of the foregoing. The compositions are useful in the the treatment of pseudobulbar affect, neuropathic pain, neurodegenerative diseases, brain injuries, and the like.

  本文提供了包含根据公式I或公式II的右美沙芬类似物或其药学上可接受的盐之一，以及辅助剂，例如抗抑郁药物，如选择性5-羟色胺和去甲肾上腺素再摄取抑制剂；5-羟色胺、去甲肾上腺素、多巴胺再摄取抑制剂；去甲肾上腺素、多巴胺再摄取抑制剂；单胺氧化酶抑制剂；选择性5-羟色胺再摄取抑制剂；三环抗抑郁药物或其中任何一种的药学上可接受的盐的组合物。这些组合物在假性球麻痹、神经痛、神经退行性疾病、脑损伤等治疗中非常有用。
• Combination of morphinan compounds and antidepressant for the treatment of pseudobulbar affect
  申请人：CONCERT PHARMACEUTICALS, INC.

  公开号：EP2397158A2

  公开（公告）日：2011-12-21

  Provided herein are compositions comprising a dextromethorphan analog according to Formula I or Formula II or a pharmaceutically acceptable salt thereof of either of the foregoing, and a co-agent, e.g., an antidepressant such as a serotonin norepinephrine reuptake inhibitor; a serotonin noradrenaline dopamine reuptake inhibitor; a norepinephrine dopamine reuptake inhibitor; a monoamine oxidase inhibitor; a selective serotonin reuptake inhibitor; and a tricyclic antidepressant or a pharmaceutically acceptable salt of any of the foregoing. The compositions are useful in the treatment of pseudobulbar affect, neuropathic pain, neurodegenerative diseases, brain injuries, and the like.

  本文提供的组合物包含根据式 I 或式 II 的右美沙芬类似物或上述任一种的药学上可接受的盐，以及一种共用试剂，例如抗抑郁剂，如 5-羟色胺去甲肾上腺素再摄取抑制剂；5-羟色胺去甲肾上腺素多巴胺再摄取抑制剂；去甲肾上腺素多巴胺再摄取抑制剂；单胺氧化酶抑制剂；选择性 5-羟色胺再摄取抑制剂；三环类抗抑郁剂或上述任一种的药学上可接受的盐。这些组合物可用于治疗假性布巴效应、神经性疼痛、神经退行性疾病、脑损伤等。
• Combination of morphinan compounds and antidepressant for the treatment of intractable and chronic pain
  申请人：CONCERT PHARMACEUTICALS, INC.

  公开号：EP2397159A2

  公开（公告）日：2011-12-21

  Provided herein are compositions comprising a dextromethorphan analog according to Formula I or Formula II or a pharmaceutically acceptable salt of either of the foregoing and a co-agent, eg., an antidepressant such as a serotonin norepinephrine reuptake inhibitor; a serotonin noradrenaline dopamine reuptake inhibitor; a norepinephrine dopamine reuptake inhibitor; a monoamine oxidase inhibitor; a selective serotonin, reuptake inhibitor; and a tricyclic antidepressant or a pharmaceutically acceptable salt of any of the foregoing. The compositions are useful in the the treatment of pseudobulbar affect, neuropathic pain, neurodegenerative diseases, brain injuries, and the like.

  本文提供的组合物包含符合式 I 或式 II 的右美沙芬类似物或上述任一物质的药学上可接受的盐和一种辅助试剂，例如抗抑郁剂，如血清素去甲肾上腺素再摄取抑制剂；血清素去甲肾上腺素多巴胺再摄取抑制剂；去甲肾上腺素多巴胺再摄取抑制剂；单胺氧化酶抑制剂；选择性血清素再摄取抑制剂；三环类抗抑郁剂或上述任一种药物学上可接受的盐。这些组合物可用于治疗假性脑梗塞、神经性疼痛、神经退行性疾病、脑损伤等。